Impact of immunosuppression in hepatitis C recurrence after liver transplantation: A controllable factor?

Current Opinion in Organ Transplantation

Volumn 8, Issue 2, 2003, Pages 146-152

  Fasola, Carlos G ^a   Klintmalm, Goran B ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33751243300     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/00075200-200306000-00003     Document Type: Review

References (46)

1. Berenguer M, Prieto M, Rayon JM, et al. Natural history of clinically compensated HCV-related graft cirrhosis following liver transplantation. Hepatology 2000, 32:852-858.
2. Forman LM, Lewis JD, Berlin JA, et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002, 122:889-896.
3. Paik SW, Tan HP, Klein AS, et al. Outcome of orthotopic liver transplantation in patients with hepatitis C. Digestive Diseases and Sciences 2002, 47(2):450-455.
4. Han SH, Martin P, Edelstein M, et al. Conversion from intravenous to intramuscular hepatitis B immune globulin in combination with lamivudine is safe and cost-effective in patients receiving long-term prophylaxis to prevent hepatitis B recurrence after liver transplantation. Liver Transpl 2003, 9:182-187.
5. Batts KP, Ludwig J. Chronic hepatitis: An update on terminology and reporting. Am J Surg Pathol 1995, 19(12):1409-1417.
6. Berenguer M, Rayon M, Prieto M, et al. Are post-transplantation protocol liver biopsies useful in the long-term? Liver Transplantation 2001, 7:790-796.
7. Fasola CG, Klintmalm GB. Hepatitis C and mycophenolate mofetil - a clarification. Liver Transpl 2002, 8(4):411-412.
8. Boker KHW, Dalley G, Pichlmayr R, et al. Long-term outcome of hepatitis C virus infection after liver transplantation. Hepatology 1997, 25:203-210.
9. Sheiner P, Schwartz ME, Mor E, et al. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995, 21:30-34.
10. Charlton M, Seaberg E, Wiesner R, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998, 28(3):823-830
11. Berenguer M, Prieto M, Cordoba J, et al. Early development of chronic active hepatitis in recurrent hepatitis C after liver transplantation: association with treatment of rejection. J Hepatol 1998, 28:756-763
12. Belli LS, de Carlis L, Rondinara G, et al. Early cyclosporine monotherapy in liver transplantation: a 5-year follow-up of a prospective, randomized trial. Hepatology 1998, 27:1524-1529.
13. Brillanti S, Vivarelli M, DeRuvo, et al. Slowly tapering off steroids protects the graft from against hepatitis C recurrence after liver transplantation. Liver Transplantation 2002, 8:884-888.
14. Gane EJ, Portmann BC, Naoumov NV, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996, 334:815-820.
15. Fasola CG, Netto GJ, Klintmalm GB, et al. Steroid maintenance and its impact in the progression of histologic hepatitis C recurrence in liver transplant recipients at one and two years post transplant: a dose-dependent benefit? American Transplant Congress, Washington, D.C., June 2003.
16. Freeman RB, Tran S, Lee YM, et al. Serum hepatitis C RNA titers after liver transplantation are not correlated with immunosuppression or hepatitis. Transplantation 1996, 61(4):542-546.
17. Krawczynski K, Beach M, Bradley DW, et al. Immunosuppression and pathogenetic studies of acute hepatitis C virus infection in chimpanzees. Hepatology 1992, 16 (2, part 2):131A.
18. Frustaci A, Calabrese F, Chimenti C, et al. Lone hepatitis C virus myocarditis responsive to immunosuppressive therapy. Chest 2002, 122:1348-1356.
19. Di Martino V, Saurini F, Samuel D, et al. Long-term longitudinal study of intrahepatic hepatitis C virus replication after liver transplantation. Hepatology 1997, 26:1343-1350.
20. Jain A, Kashyap R, Marsh W, et al. Reasons for long-term use of steroids in primary adult liver transplantation under tacrolimus. Transplantation 2001, 17:1102-1106.
21. Hunt J, Gordon FD, Lewis DW, et al. Histological recurrence and progression of hepatitis C after orthotopic liver transplantation: influence of immunosuppression regimens. Liver Transplantation 2001, 7(12):1056-1063.
22. Neyts J, Meerbach A, McKenna P, et al. Use of the yellow fever virus vaccine strain 17D for the study of strategies for the treatment of yellow fever virus infections. Antiviral Res 1996, 30(2-3):125-132.
23. Eckhoff DE, McGuire BM, Frenette LR, et al. Tacrolimus (FK506) and mycophenolate mofetil combination therapy versus tacrolimus in adult liver transplantation. Transplantation 1998, 65(2):180-187.
24. McDiarmid SV. Mycophenolate mofetil as induction therapy after liver transplantation. Liver Transpl Surg 1999, 5(4 suppl 1):S85-S89.
25. Smallwood AG, Davis L, Stieber A, et al. Mycophenolate Mofetil's Antiviral Activity and Influence on Recurrence of Hepatitis C Following Liver Transplantation. Hepatology 2000, 32(4) Pt. 2:343A.
26. Berenguer M, Ferrell L, Watson J, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatology 2000, 32:673-684.
27. Fasola CG, Netto GJ, Klintmalm GB, et al. Delay of hepatitis C recurrence in liver transplant recipients: impact of mycophenolate mofetil on transplant recipients with severe acute rejection or with renal dysfunction. Transpl Proceedings 2002, 34(5):1561-1562.
28. Wiesner R, Rabkin J, Klintmalm, et al. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transplantation 2001, 7(5):442-450.
29. Fasola CG, Netto GJ, Klintmalm GB, et al. Lower incidences of early hepatitis C-RNA levels and HCV recurrence post liver transplantation in patients induced with mycophenolate mofetil: a high-dose benefit. Am J Transplantation 2002, 3(2):196-196A.
30. Firpi RJ, Nelson DR, Davis GL. Lack of antiviral effect of a short course of mycophenolate mofetil in patients with chronic hepatitis C virus infection. Liver Transplantation 2003, 9(1):57-61.
31. Fasola CG, Netto GJ, Klintmalm GB, et al. Recurrence of hepatitis C in liver transplant recipients treated with mycophenolate mofetil. Transpl Proceedings 2002, 34(5):1563-1564.
32. Fasola CG, Netto GJ, Klintmalm GB, et al. Optimal dosing of mycophenolate mofetil is necessary to delay hepatitis C recurrence in liver transplant recipients. Am J Transplantation 2001, 1(1):202A.
33. O'Hair DP, McManus RP, Komorowski R. Inhibition of chronic vascular rejection in primate cardiac xenografts using mycophenolate mofetil. Ann Thorac Surg 1994, 58(5):1311-1315.
34. Heinz C, Huddle T, Heise K, et al. Antiproliferative effect of mycophenolate mofetil on culture of human Tenon fibroblasts. Graefes Arch Clin Exp Ophtalmol 2002, 240(5):408-414.
35. Rosen HR, Shackleton CR, Higa L, et al. Use of OKT3 is associated with early and severe recurrence of hepatitits C after liver transplantation. Am J Gastroenterol 1997, 92:1453.
36. Prieto M, Berenguer M, Rayon JM, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following liver transplantation: relationship with rejection episodes. Hepatology 1999, 29:250-256.
37. Testa G, Crippin JS, Klintmalm GB, et al. Liver transplantation for hepatitis C: Recurrence and disease progression in 300 patients. Liver Transpl 2000, 6(5): 553-561.
38. Eason JD, Loss GE, Blazek J, et al. Steroid-free liver transplantation using rabbit antithymocyte globulin induction: results of a prospective randomized trial. Liver Transpl 2001, 7(8):693-697.
39. Pinna AD, Ricordi C, Weppler D, et al. Treatment of recurrent hepatitis C after liver transplantation with IL-2R [abstract]. Transpl Proceedings 2001, 33(1-2):1087-1089.
40. McAlister VC, Peltekian KM, Malatjalian DA, et al. Orthotopic liver transplantation using low-dose tacrolimus and sirolimus. Liver Transpl 2001, 7(8): 701-798.
41. Schluger LK, Sheiner PA, Bodenheimer HC, et al. Severe recurrent hepatitis C following orthotopic liver transplantation. Hepatology 1996, 23:971-976.
42. Ghobrial RM, Farmer DG, Busuttil RW, et al. Orthotopic liver transplantation for hepatitis C. Outcome, effect of immunosuppression, and causes of retransplantation during an 8-year single center experience. Annals of Surgery 1999, 229(6):824-833.
43. Sheiner PA, Schluger LK, Schwarts ME, et al. Retransplantation for recurrent hepatitis C. Liver Transpl and Surg 1997, 3(2):130-136.
44. Zervos XA, Weppler D, Kato T, et al. Comparison of tacrolimus with microemulsion cyclosporine as primary immunosuppression in hepatitis c patients after liver transplantation. Transplantation 1998, 65(7):1044-1046.
45. Wiesner RH. A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation. A report of the US FK506 study group. Transplantation 1998, 66:493-499.
46. Charlton M, Seaberg E, Wiesner R, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998, 28(3):823-830.